[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100322927":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":30,"centralContacts":34,"locations":39,"responsibleParty":56,"collaborators":21,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":21,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":21,"enrollmentInfo":68,"targetDuration":21,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":21,"overallStatus":41,"whyStopped":21,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"University of Louisville","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"Treatment","Irreversible electroporation and treatment with either FOLFIRINOX or Gemcitabine (based upon which chemotherapy regimen received prior to IRE)",[12,13,14],"Procedure: Irreversible Electroporation (IRE)","Drug: Gemcitabine","Drug: FOLFIRINOX",[16,22,27],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"PROCEDURE","Irreversible Electroporation (IRE)","Non-thermal ablation of tumor",[9],null,{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":21},"DRUG","Gemcitabine","25% dose - first 3 enrolled; 50% dose - next 3 enrolled; 75% dose - remaining 4 enrolled",[9],{"type":23,"name":28,"description":25,"armGroupLabels":29,"otherNames":21},"FOLFIRINOX",[9],[31],{"name":32,"affiliation":5,"role":33},"Robert Martin, MD, PhD","PRINCIPAL_INVESTIGATOR",[35],{"name":32,"role":36,"phone":37,"phoneExt":21,"email":38},"CONTACT","502-629-3355","robert.martin@louisville.edu",[40],{"facility":5,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"RECRUITING","Louisville","Kentucky","40202","United States","US",{"type":48,"coordinates":49},"Point",[50,51],-85.75941,38.25424,{"lat":51,"lon":50},[54,55],{"name":32,"role":36,"phone":37,"phoneExt":21,"email":38},{"name":32,"role":33,"phone":21,"phoneExt":21,"email":21},{"type":33,"investigatorFullName":57,"investigatorTitle":58,"investigatorAffiliation":5,"oldNameTitle":21,"oldOrganization":21},"Robert C. Martin","Principal Investigator","100322927","phase-1-chemotherapy-and-irreversible-electroporation-in-the-treatment-of-advanced-pancreatic-adenocarcinoma-100322927",false,"NCT03484299","Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma","Chemotherapy and Irreversible Electroporation (IRE) in the Treatment of Advanced Pancreatic Adenocarcinoma","Inclusion Criteria:\n\n* greater than or equal to 18 years of age\n* diagnosed with stage III pancreatic cancer\n* tumor is measurable\n* GFR \\> mL\u002Fmin\u002F1.73m2\n* willing and able to comply with protocol requirements\n* AST\u002FALT \\>3 times upper limit of normal\n* stable surgical post-operative course as defined by operative surgeon\n\nExclusion Criteria:\n\n* participating in another clinical trial for the treatment of cancer at the time of screening\n* pregnant or currently breast feeding\n* have a cardiac pacemaker or ICD implanted that cannot be deactivated during IRE procedure\n* have non-removable implants with metal parts within 1 cm of the target lesion\n* had a myocardial infarction within 3 months prior to enrollment","ALL","18 Years",{"count":69,"type":70},20,"ESTIMATED","INTERVENTIONAL",[73],"PHASE1","Compare the efficacy and tolerability of IRE in combination with either FOLFIRINOX or gemcitabine in patients with locally advanced pancreatic cancer.",[76],"Pancreas Cancer","2025-10-27",{"date":79,"type":80},"2025-10-29","ACTUAL",{"date":82,"type":80},"2018-05-30",{"date":84,"type":70},"2027-07-31",{"name":5,"class":6},1]